Citations

Clear

410 citation(s) found for "Shu, Yu".

Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial
Jatoi, Aminah , Ahn, Daniel H. , Ciombor, Kristen K. , Jacobs, Nisha L. , Pasche, Boris , Cleary, James M. , McCune, Jeannine S. , Pedersen, Katrina S. , Chiorean, E. Gabriela , Heying, Erica N., Lenz, Heinz‐Josef , Sloan, Jeff A. , Bekaii‐Saab, Tanios , Zemla, Tyler J, Bekaii-Saab, Tanios S , Pedersen, Katrina , Ou, Fang‐Shu , Zemla, Tyler , Le‐Rademacher, Jennifer , Boland, Patrick M. , Barzi, Afsaneh , Grothey, Axel , Lacouture, Mario E.

Mayo Clinic

The Oncologist | February 19, 2021 | Volume: 26 | Issue: 7 | Pages: 610-618

10.1002/onco.13730 | PMID 33604969 Get It

Abstract Background Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials and Methods The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously published trial with a 1:1:1:1 randomization scheme, was analyzed in a manner in keeping with the original protocol to assess whether clobetasol 0.05% cream (a corticosteroid) applied to the palms and soles twice per day for 8 weeks was more effective when prescribed preemptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the first two cycles of regorafenib. Results Sixty-one patients received preemptive clobetasol, and 55 received reactive clobetasol. Groups were balanced on demographics. Over the first two cycles, no evidence of HFSR occurred in 30% with preemptive clobetasol versus 13% with reactive clobetasol (p = .03). During the first cycle, 54% and 45% of patients had no HFSR with preemptive and reactive clobetasol, respectively (p = .35). During the second cycle, 33% and 15% had no HFSR with preemptive and reactive clobetasol, respectively (p = .02). During the second cycle, rates of grade 1, 2, and 3 HFSR were 30%, 8%, and 3%, respectively, with preemptive clobetasol and 43%, 18%, and 7%, respectively, with reactive clobetasol (p = .12). Patient-reported outcomes showed HFSR compromised nearly all activities of daily living with worse quality of life in patients who received reactive versus preemptive clobetasol. No clobetasol-induced adverse events were reported. Conclusion Preemptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. Implications for Practice Regorafenib causes hand-foot skin reactions. Preemptive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.
Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3
Mocci, Evelina, Kundu, Prosenjit, Wheeler, William, Arslan, Alan A. , Beane-Freeman, Laura E., Bracci, Paige M., Brennan, Paul , Canzian, Federico , Du, Mengmeng, Gallinger, Steven, Goodman, Phyllis J., Kooperberg, Charles, Marchand, Loic Le, Neale, Rachel E., Shu, Xiao-Ou, Visvanathan, Kala , White, Emily, Zheng, Wei, Albanes, Demetrius, Andreotti, Gabriella, Babic, Ana, Berndt, Sonja I., Bueno-de-Mesquita, Bas, Buring, Julie E., Campa, Daniele, Chanock, Stephen J., Childs, Erica J., Fuchs, Charles S., Gaziano, J. Michael, Giovannucci, Edward L., Goggins, Michael G., Hartge, Patricia, Hassan, Manal M., Holly, Elizabeth A., Hoover, Robert N., Kurtz, Robert C., Lee, I-Min, Ng, Kimmie, Oberg, Ann L. , Panico, Salvatore, Peters, Ulrike, Porta, Miquel, Rabe, Kari G. , Riboli, Elio, Rothman, Nathaniel, Scelo, Ghislaine, Sesso, Howard D. , Silverman, Debra T., Stevens, Victoria L. , Strobel, Oliver , Thompson, Ian M., Tjønneland, Anne , Trichopoulou, Antonia, Wactawski‐Wende, Jean , Wentzensen, Nicolas, Wilkens, Lynne R., Yuan, Fangcheng , Zeleniuch-Jacquotte, Anne, Li, Donghui , Jacobs, Eric J., Petersen, Gloria M., Wolpin, Brian M., Risch, Harvey A., Kraft, Peter, Chatterjee, Nilanjan, Ríboli, Elio , Zeleniuch‐Jacquotte, Anne , Thompson, Ian M. , Mocci, Evelina , Porta, Miquel , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Chaffee, Kari G. , Sesso, Howard D , Stevens, Victoria L , Strobel, Oliver , Tjønneland, Anne , Van Den Eeden, Stephen K , Wactawski-Wende, Jean , Yu, Herbert , Yuan, Fangcheng , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Arslan, Alan A , Canzian, Federico , Riboli, Elio , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Kundu, Prosenjit, Wheeler, William, Beane-Freeman, Laura E., Bracci, Paige M., Brennan, Paul , Du, Mengmeng, Gallinger, Steven, Goodman, Phyllis J., Kooperberg, Charles, Marchand, Loic Le, Neale, Rachel E., Shu, Xiao-Ou, White, Emily, Zheng, Wei, Albanes, Demetrius, Andreotti, Gabriella, Babic, Ana, Berndt, Sonja I., Bueno-de-Mesquita, Bas, Buring, Julie E., Campa, Daniele, Chanock, Stephen J., Childs, Erica J., Fuchs, Charles S., Gaziano, J. Michael, Giovannucci, Edward L., Goggins, Michael G., Hartge, Patricia, Hassan, Manal M., Holly, Elizabeth A., Hoover, Robert N., Kurtz, Robert C., Lee, I-Min, Ng, Kimmie, Panico, Salvatore, Peters, Ulrike, Rothman, Nathaniel, Scelo, Ghislaine, Silverman, Debra T., Thompson, Ian M., Trichopoulou, Antonia, Wentzensen, Nicolas, Wilkens, Lynne R., Jacobs, Eric J., Petersen, Gloria M., Wolpin, Brian M., Risch, Harvey A., Kraft, Peter, Chatterjee, Nilanjan

Mayo Clinic

Cancer Research | February 11, 2021 | Volume: 81 | Issue: 11 | Pages: 3134-3143

10.1158/0008-5472.can-20-3267 | PMID 33574088 Get It

Abstract Germline variation and smoking are independently associated with pancreatic ductal adenocarcinoma (PDAC). We conducted genome-wide smoking interaction analysis of PDAC using genotype data from four previous genome-wide association studies in individuals of European ancestry (7,937 cases and 11,774 controls). Examination of expression quantitative trait loci data from the Genotype-Tissue Expression Project followed by colocalization analysis was conducted to determine whether there was support for common SNP(s) underlying the observed associations. Statistical tests were two sided and P < 5 × 10–8 was considered statistically significant. Genome-wide significant evidence of qualitative interaction was identified on chr2q21.3 in intron 5 of the transmembrane protein 163 (TMEM163) and upstream of the cyclin T2 (CCNT2). The most significant SNP using the Empirical Bayes method, in this region that included 45 significantly associated SNPs, was rs1818613 [per allele OR in never smokers 0.87, 95% confidence interval (CI), 0.82–0.93; former smokers 1.00, 95% CI, 0.91–1.07; current smokers 1.25, 95% CI 1.12–1.40, Pinteraction = 3.08 × 10–9). Examination of the Genotype-Tissue Expression Project data demonstrated an expression quantitative trait locus in this region for TMEM163 and CCNT2 in several tissue types. Colocalization analysis supported a shared SNP, rs842357, in high linkage disequilibrium with rs1818613 (r2 = 0. 94) driving both the observed interaction and the expression quantitative trait loci signals. Future studies are needed to confirm and understand the differential biologic mechanisms by smoking status that contribute to our PDAC findings. Significance: This large genome-wide interaction study identifies a susceptibility locus on 2q21.3 that significantly modified PDAC risk by smoking status, providing insight into smoking-associated PDAC, with implications for prevention.
Temperature‐corrected proton density fat fraction estimation using chemical shift‐encoded MRI in phantoms
Navaratna, Ruvini , Zhao, Ruiyang , Colgan, Timothy J. , Hu, Peng , Bydder, Mark , Bashir, Mustafa R. , Middleton, Michael S. , Serai, Suraj D. , Chenevert, Thomas L. , Smith, Mark A. , Henderson, Walter C. , Hamilton, Gavin , Shu, Yunhong , Tkach, Jean A. , Brittain, Jean H. , Hu, Houchun Harry , Serai, Suraj D , Shu, Yunhong , Trout, Andrew T , Hernando, Diego , Reeder, Scott B. , Hamilton, Gavin , Yokoo, Takeshi , Malyarenko, Dariya I. , Sirlin, Claude B. , Trout, Andrew T.

Mayo Clinic

Magnetic Resonance in Medicine | February 11, 2021 | Volume: 86 | Issue: 1 | Pages: 69-81

10.1002/mrm.28669 | PMID 33565112 Get It

PurposeChemical shift‐encoded MRI (CSE‐MRI) is well‐established to quantify proton density fat fraction (PDFF) as a quantitative biomarker of hepatic steatosis. However, temperature is known to bias PDFF estimation in phantom studies. In this study, strategies were developed and evaluated to correct for the effects of temperature on PDFF estimation through simulations, temperature‐controlled experiments, and a multi‐center, multi‐vendor phantom study.Theory and MethodsA technical solution that assumes and automatically estimates a uniform, global temperature throughout the phantom is proposed. Computer simulations modeled the effect of temperature on PDFF estimation using magnitude‐, complex‐, and hybrid‐based CSE‐MRI methods. Phantom experiments were performed to assess the temperature correction on PDFF estimation at controlled phantom temperatures. To assess the temperature correction method on a larger scale, the proposed method was applied to data acquired as part of a nine‐site multi‐vendor phantom study and compared to temperature‐corrected PDFF estimation using an a priori guess for ambient room temperature.ResultsSimulations and temperature‐controlled experiments show that as temperature deviates further from the assumed temperature, PDFF bias increases. Using the proposed correction method and a reasonable a priori guess for ambient temperature, PDFF bias and variability were reduced using magnitude‐based CSE‐MRI, across MRI systems, field strengths, protocols, and varying phantom temperature. Complex and hybrid methods showed little PDFF bias and variability both before and after correction.ConclusionCorrection for temperature reduces temperature‐related PDFF bias and variability in phantoms across MRI vendors, sites, field strengths, and protocols for magnitude‐based CSE‐MRI, even without a priori information about the temperature.
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
Morra, Anna , Jung, Audrey , Behrens, Sabine , Keeman, Renske , Ahearn, Thomas U. , Arndt, Volker , Augustinsson, Annelie , Auvinen, Päivi , Becher, Heiko , Beckmann, Matthias W. , Bojesen, Stig E. , Bolla, Manjeet K. , Brenner, Hermann , Camp, Nicola J. , Campa, Daniele , Castelao, Jose E. , Choi, Ji‐Yeob , Cox, Angela , Easton, Douglas F. , Eccles, Diana M., Egan, Kathleen M. , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Gago-Domínguez, Manuela , Gapstur, Susan M. , Gaudet, Mia M. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute, Hartman, Mikael , Heyworth, Jane , Hoppe, Reiner , Hopper, John L. , Hunter, David J. , Jager, Agnes , Jakimovska, Milena , Janni, Wolfgang , Koutros, Stella , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Mannermaa, Arto , Manoochehri, Mehdi, Margolin, Sara , Mariapun, Shivaani, Mavroudis, Dimitrios, Muranen, Taru , Newman, William G. , Noh, Dong‐Young , Nordestgaard, Børge G. , Obi, Nadia , Olsson, Håkan , Park‐Simon, Tjoung‐Won , Petridis, Christos , Plaseska‐Karanfilska, Dijana , Rashid, Muhammad Usman , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Sawyer, Elinor J. , Schneeweiß, Andreas , Schwentner, Lukas , Shah, Mitul , Shen, Chen‐Yang , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wang, Qin , Wang, Sophia , Williams, Justin A. , Winqvist, Robert , Wu, Anna H. , Yoo, Keun-Young, Yu, Jyh‐Cherng , Zheng, Wei , Yang, Xiaohong R. , Eliassen, A. Heather , García‐Closas, Montserrat , Teo, Soo‐Hwang , Chang‐Claude, Jenny , Eccles, Diana , Khaw, Kay‐Tee , Lambrechts, Diether , Arndt, Volker , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Canzian, Federico , Cox, Angela , Dunning, Alison M , Evans, D Gareth , Fasching, Peter A , Gago-Dominguez, Manuela , García-Sáenz, José A , Gaudet, Mia M , Giles, Graham G , Guénel, Pascal , Hall, Per N , Hart, Steven N , Hartman, Mikael , Ito, Hidemi , Jager, Agnes , Jakubowska, Anna , Janni, Wolfgang , Kaaks, Rudolf , Kapoor, Pooja Middha , Koutros, Stella , Lambrechts, Diether , Li, Jingmei , Matsuo, Keitaro , Milne, Roger L , Muranen, Taru A , Newman, William G , Park-Simon, Tjoung-Won , Pharoah, Paul D P , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Schneeweiss, Andreas , Scott, Christopher , Southey, Melissa C , Stram, Daniel O. , Tamimi, Rulla M , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wolk, Alicja , Ziogas, Argyrios , Holmes, Michelle D , García-Closas, Montserrat , Teo, Soo H , Schmidt, Marjanka K , Chang-Claude, Jenny , Lambrechts, Diether , Behrens, Sabine , Eccles, Diana , Keeman, Renske , Zheng, Wei , Wang, Sophia S , Jung, Audrey Y , Becher, Heiko , Eliassen, A Heather , Håkansson, Niclas , Rashid, Muhammad U , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Anton‐Culver, Hoda , Freeman, Laura E. Beane , Blomqvist, Carl , Briceño, Ignacio , Brucker, Sara Yvonne , Canzian, Federico , Chanock, Stephen Jacob , Clarke, Christine L. , Couch, Fergus J. , Cross, Simon S. , Czene, Kamila , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , García-Sáenz, José Á. , Giles, Graham G. , Han, Sileny , Hart, Steven N. , Ito, Hidemi , Jakubowska, Anna , Kaaks, Rudolf , Kang, Daehee , Middha, Pooja , Kitahara, Cari M. , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Lush, Michael J. , Manoochehri, Mehdi, Matsuo, Keitaro , Milne, Roger L. , Olshan, Andrew F. , Pharoah, Paul D.P. , Presneau, Nadège , Scott, Christopher G. , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Tapper, William , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Ziogas, Argyrios , Schmidt, Marjanka K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 26, 2021 | Volume: 30 | Issue: 4 | Pages: 623-642

10.1158/1055-9965.epi-20-0924 | PMID 33500318 Get It

Abstract Background: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. Methods: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer–specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. Results: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (Padj > 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5–25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06–1.34)]; current versus never smoking [1.37 (1.27–1.47)], high versus low physical activity [0.43 (0.21–0.86)], age ≥30 years versus <20 years at first pregnancy [0.79 (0.72–0.86)]; >0–<5 years versus ≥10 years since last full-term birth [1.31 (1.11–1.55)]; ever versus never use of oral contraceptives [0.91 (0.87–0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen–progestin therapy [0.61 (0.54–0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02–1.21) for current versus never smoking. Conclusions: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. Impact: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Cercek, Andrea , Ng, Kimmie , Sanchez, Federico Augusto, Bruggeman, Sarah, Larson, Joseph J. , Finley, Gene Grant, Lenz, Heinz‐Josef , Corcoran, Ryan B. , Strickler, John H. , Ou, Fang‐Shu , Bekaii‐Saab, Tanios , Parseghian, Christine Megerdichian , Hubbard, Joleen M. , Wu, Christina , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: TPS143-TPS143

10.1200/jco.2021.39.3_suppl.tps143 Get It

TPS143 Background: Patients with KRAS and NRAS ( RAS) wild-type mCRC benefit from the epidermal growth factor receptor (EGFR) monoclonal antibodies (Abs) panitumumab and cetuximab, but nearly all patients experience resistance. Blood-based profiling of cell free DNA (cfDNA) can identify genomic alterations that drive acquired EGFR Ab resistance. After discontinuation of anti-EGFR Abs, acquired genomic alterations decay over time to undetectable levels. Some studies have suggested clinical benefit from EGFR Ab rechallenge, but there is limited evidence that EGFR Ab rechallenge improves survival compared to standard of care (SOC) therapies. We hypothesize that cfDNA profiling will identify patients appropriate for panitumumab rechallenge, and that these molecularly selected patients will have improved survival compared to current SOC therapies. Methods: This is a randomized phase II, open label study designed to compare the overall survival (OS) of panitumumab rechallenge versus SOC (investigator choice TAS-102 or regorafenib). Secondary objectives include comparisons of progression free survival, objective response rate, clinical benefit rate, and quality of life as measured by the linear analogue self-assessment (LASA) questionnaire. Eligible patients have radiographically measurable KRAS, NRAS, and BRAF codon 600 wild-type mCRC based on tumor tissue testing, and must have experienced progression or intolerance to treatment with a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF Ab, and an anti-PD-1 Ab if the tumor has mismatch repair deficiency or is MSI-H. Progression after at least 4 months treatment with an anti-EGFR Ab is required. All patients must be enrolled in the COLOMATE cfDNA screening protocol (NCT03765736) and meet molecular eligibility based on Guardant360 cfDNA profiling (absence of amplification of ERBB2, KRAS, NRAS, and MET; absence of mutations of BRAF, EGFR, ERBB2, KRAS, NRAS, and MET [mutant allele frequency > 0.5%]). Greater than 90 days must have elapsed between the most recent treatment with an anti-EGFR Ab and cfDNA profiling. Dosing for all study drugs is according to clinical SOC. 120 patients will be randomized 1:1 to panitumumab rechallenge or SOC. With 83 OS events, this study will have 80% power to detect an improvement in median OS from 6.5 to 10 months (HR=0.65; 1-sided α= 0.15). This study began enrollment in 6/2020. Recruitment is ongoing at 16 sites in the Academic and Community Cancer Research United (ACCRU) network (ACCRU-GI-1623). Clinical trial information: NCT03992456.
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation
Nie, Wei , Gan, Lu , Wang, Xin , Gu, Kai , Qian, Fang-Fei, Hu, Min-Juan, Chen, Shi-Qing, Lü, Jun , Cao, Shu-Hui, Li, Jing-Wen, Zhang, Bo , Wang, Shu-Yuan, Li, Chang-Hui, Xu, Midie , Zhang, Xue-Yan, Zhong, Hua , Han, Bao-Hui , Gu, Kai, Zhang, Ding , Wang, Yue , Yang, Ping

Mayo Clinic

OncoImmunology | January 15, 2021 | Volume: 10 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1865670 | PMID 33537171 Get It

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Sobrero, Alberto , Yoshino, Takayuki , Souglakos, Ioannis , Ou, Fang‐Shu , Meyers, Jeffrey P., Shi, Qian , Saunders, Mark , Yamanaka, Takeharu , Boukovinas, Ioannis , Holländer, Niels Henrik , Yamazaki, Kentaro , Harkin, Andrea , Paul, James , Iveson, Timothy J , Sobrero, Alberto F , Yoshino, Takayuki , Ou, Fang-Shu , Shi, Qian , Yamanaka, Takeharu , Hollander, Niels H , Oki, Eiji , Lonardi, Sara , Harkin, Andrea , Rosati, Gerardo , Paul, James , Iveson, Timothy , Grothey, Axel , Labianca, Roberto , Galli, Fabio , Georgoulias, Vassilis , Kerr, Rachel , Oki, Eiji , Lonardi, Sara

Mayo Clinic

Journal of Clinical Oncology | January 13, 2021 | Volume: 39 | Issue: 6 | Pages: 631-641

10.1200/jco.20.01330 | PMID 33439695 Get It

PURPOSE: As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers. PATIENTS AND METHODS: Four of the six studies in the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration included patients with high-risk stage II colon and rectal cancers. Patients were treated (clinician and/or patient choice) with either fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) and randomly assigned to receive 3- or 6-month treatment. The primary end point is disease-free survival (DFS), and noninferiority of 3-month treatment was defined as a hazard ratio (HR) of < 1.2- v 6-month arm. To detect this with 80% power at a one-sided type one error rate of 0.10, a total of 542 DFS events were required. RESULTS: 3,273 eligible patients were randomly assigned to either 3- or 6-month treatment with 62% receiving CAPOX and 38% FOLFOX. There were 553 DFS events. Five-year DFS was 80.7% and 83.9% for 3-month and 6-month treatment, respectively (HR, 1.17; 80% CI, 1.05 to 1.31; P [for noninferiority] .39). This crossed the noninferiority limit of 1.2. As in the IDEA stage III analysis, the duration effect appeared dependent on the chemotherapy regimen although a test of interaction was negative. HR for CAPOX was 1.02 (80% CI, 0.88 to 1.17), and HR for FOLFOX was 1.41 (80% CI, 1.18 to 1.68). CONCLUSION: Although noninferiority has not been demonstrated in the overall population, the convenience, reduced toxicity, and cost of 3-month adjuvant CAPOX suggest it as a potential option for high-risk stage II colon cancer if oxaliplatin-based chemotherapy is suitable. The relative contribution of the factors used to define high-risk stage II disease needs better understanding.
Clioquinol reduces tau phosphorylation and oligomerization
Zhu, Feiyan , Lin, Gaoping, Kanaan, Nicholas M. , Yen, Shu‐Hui, Asano, Rei, Shirafuji, Norimichi, Sasaki, Hirohito, Enomoto, Soichi, Yamaguchi, Tomohisa, Ueno, Asako , Yamamura, Osamu , Nakamoto, Yasunari , Zhu, Feiyan, Hamano, Tadanori , Ikawa, Masamichi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S3 | Pages: No page available

10.1002/alz.044356 Get It

AbstractBackgroundThe pathological features of AD are neurofibrillary tangles (NFTs) composed of highly phosphorylated tau and senile plaques (SPs) composed of amyloid β protein (Aβ). It was suggested that Cu2 + induced hyperphosphorylation of tau and Zn2 + deposits on SPs. Clioquinol (CQ) has a mild chelating effect on Zn2 + and Cu2 +. In addition, CQ has been shown to reduce Aβ aggregation by removing Zn2+ from SPs. However, the effect of CQ on tau aggregation is not fully understood. The purpose of our study is to examine the effect of CQ on tau metabolism by using a cell culture model of tauopathy.MethodsHuman neuroblastoma cell line M1C cells that express wild‐type tau protein (4R0N) via tetracycline (Tet) off induction was used. M1C cells were exposed to 0.1‐10 μM CQ on day 4 of Tet‐Off induction, and harvested at the end of Day 5. Total tau detected by Tau5, and phosphorylated tau detected by PS199/202, AT180, AT270, CP13, and PHF‐1 antibodies, were examined using Western blot analysis. Immunocytochemical studies, fractional analysis and immunoprecipitation of ubiquitinated tau were also performed. Tau kinases including c‐Jun N‐terminal kinase (JNK), and P38 MAPK and tau phosphatase, protein phosphatase 2A (PP2A) were also examined. C‐terminal truncated pathological tau was detected by using the antibody TauC3. In addition, autophagy and proteasome activity were also examined.ResultPhosphorylated tau levels were reduced by 1‐10 μM CQ treatment. Tau kinases, JNK and p38 MAPK were inactivated by CQ treatment. Interestingly, activation of the tau phosphatase PP2A was also observed with CQ treatment. Fractionation studies showed that CQ treatment reduced AT180 and AT270 positive high molecular weight tau in the Tris‐insoluble, sarkosyl‐soluble fraction. CQ also reduced tau oligomer specific antibody TOC1‐positive oligomeric tau. CQ reduced caspase‐cleaved tau detected by antibody TauC3. P62 levels were reduced by CQ treatment, suggesting that CQ activates autophagy. In addition, CQ slightly reduced high molecular weight ubiquitinated tau. This implies activation of the ubiquitin‐proteasome by CQ.ConclusionCQ could provide beneficial effects against pathogenic forms of tau via multiple mechanisms and may represent a viable therapeutic approach for AD and other tauopathies.
Syk inhibitor reduces oligomeric tau associated with GSK3β inactivation and autophagy activation
Yamaguchi, Tomohisa, Kanaan, Nicholas M. , Sasaki, Hirohito, Yen, Shu‐Hui, Asano, Rei, Enomoto, Soichi, Shirafuji, Norimichi, Ueno, Asako , Yamamura, Osamu , Nakamoto, Yasunari , Hamano, Tadanori , Sada, Kiyonao , Ikawa, Masamichi

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S3 | Pages: No page available

10.1002/alz.042633 Get It

AbstractBackgroundNeurofibrillary tangle (NFT), composed of highly phosphorylated tau is one of the pathological hallmarks of Alzheimer’s disease (AD). Spleen tyrosine kinase (Syk) is non receptor type tyrosine kinase, and has various physiological functions, including histamine release in mast cells, phagocytosis in macrophage, and B cell differentiation. The possibility of Syk inhibitor for clinical application was proposed in allergic rhinitis, rheumatoid arthritis, and immunologic thrombocytopenia. The possible relationship between Syk and AD has been reported recently. We have examined the effects of Syk specific inhibitor BAY61‐3606 on phosphorylation levels of tau protein and oligomeric tau by using cell culture model of tauopathy, M1C cells.MethodsWe utilized human neuroblastoma cell line M1C cells, which expresses wild type tau protein (4R0N) via tetracycline off induction (Tet Off induction). Reduction of phosphorylated tau protein and oligomeric tau protein by Syk inhibitor was examined by using various phospho‐tau antibodies, and tau oligomer specific antibody. Influences of activity of autophagy by Syk inhibitor was also examined by western blot analysis.ResultsIn this cell line, 72kDa of Syk protein was identified by Western blot analysis. Phosphorylated tau detected by various phospho‐tau antibodies, including PHF‐1, CP13, and AT270 was decreased by 1, 10 μM of Syk inhibitor. One of the patholoigical form of tau, caspase cleaved tau detected by TauC3 was also decreased by Syk inhibitor. Oligomeric tau, which detected by tau oligomer specific antibody, TOC1 was also decreased by Syk inhibitor. Syk inhibitor also inactivated glycogen synthase kinase 3β (GSK3β). Syk inhibitor upregulated autophagy detected by increase of LC3‐II, and reduction of P62. In summary, Syk inhibitor decreased phosphorylated tau as well as total tau by upregulating autophagy, and inactivating tau kinases, including GSK3β. Finally, oligomeric tau was reduced by Syk inhibitor.ConclusionSyk inhibitor may have promising for the treatment of tauopathy, including AD.